Top-News
Pharmazeutika USA

Merrimack Pharmaceuticals Inc News

Aktie
WKN:  A2DW3Q ISIN:  US5903282094 US-Symbol:  MACK
15,15 $
+0,02 $
+0,13%
17.05.24 21:55:52
Handeln Depot/Watchlist
Aktienanzahl *
14,32 Mio.
Marktkapitalisierung *
200,17 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 16.02.2024

Merrimack Pharmaceuticals Inc News

06.09.18 - PR Newswire
Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC) PR Newswire
07.08.18 - PR Newswire
Merrimack Reports Second Quarter 2018 Financial Results
Merrimack Reports Second Quarter 2018 Financial Results - $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-​dilutive ...
31.07.18 - PR Newswire
Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call
Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call PR Newswire
02.07.18 - PR Newswire
Merrimack Secures $25 Million Debt Facility with Hercules Capital
Merrimack Secures $25 Million Debt Facility with Hercules Capital - Non-​dilutive financing strengthens cash position - - Multiple clinical read-outs expected later this year - PR Newswire
25.06.18 - PR Newswire
Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer
Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-​Line Metastatic Pancreatic Cancer - CARRIE study did not meet primary or secondary ...
29.05.18 - PR Newswire
Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting
Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting PR Newswire
08.05.18 - PR Newswire
Merrimack Reports First Quarter 2018 Financial Results
Merrimack Reports First Quarter 2018 Financial Results - Three clinical readouts expected in 2018, including data from two randomized Phase 2 studies - - Conference call at 8:30 ...
01.05.18 - PR Newswire
Merrimack Announces Timing of First Quarter 2018 Investor Conference Call
Merrimack Announces Timing of First Quarter 2018 Investor Conference Call PR Newswire
09.04.18 - PR Newswire
Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting
Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting PR Newswire
12.03.18 - PR Newswire
Merrimack Provides Business Update and Reports 2017 Financial Results
Merrimack Provides Business Update and Reports 2017 Financial Results - Strengthened the randomized Phase 2 SHERLOC study evaluating MM-121 in non-small cell lung ...
12.03.18 - PR Newswire
Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer
Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer Randomized Phase 2 study accrual raised to 100 patients; data still expected later this year PR ...
05.03.18 - PR Newswire
Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference
Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference PR Newswire
26.02.18 - PR Newswire
Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer
Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-​Menopausal Metastatic Breast Cancer PR Newswire
20.02.18 - PR Newswire
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology Members include world-​renowned experts in biomarker-​defined ...
15.02.18 - PR Newswire
Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference
Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference PR Newswire
30.11.17 - PR Newswire
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors PR Newswire
14.11.17 - PR Newswire
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-​Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran ...
08.11.17 - PR Newswire
Merrimack Reports Third Quarter 2017 Financial Results
Merrimack Reports Third Quarter 2017 Financial Results - Received orphan drug designation for MM-121 in heregulin positive non-small cell lung cancer - - Resolved convertible ...
01.11.17 - PR Newswire
Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call
Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call PR Newswire
30.10.17 - PR Newswire
Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer
Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer PR Newswire

Newssuche

Videos

newspaper
08:45 Uhr
Technical Trading: Sojabohnen im saisonalen Trend
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »